 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
20188 News |  |
| «12...197198199200201202203204205206207208209» |
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
New P3 trial: SPIRIT A1: Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) (clinicaltrials.gov) - Jun 4, 2013
P3, N=0, Withdrawn, Sponsor: Eli Lilly and Company
- Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Enrollment closed: Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker (clinicaltrials.gov) - Jun 4, 2013
P4, N=100, Active, not recruiting, Sponsor: University of Sao Paulo
Recruiting --> Active, not recruiting
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, PK/PD data: A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety (clinicaltrials.gov) - Jun 2, 2013
P2, N=100, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial: VIP-Et: Vascular Inflammation in Psoriasis - Extension Study (clinicaltrials.gov) - May 29, 2013
P4, N=96, Recruiting, Sponsor: University of Pennsylvania
- pateclizumab (RG7416) / Roche
Enrollment change, Combination therapy: A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - May 21, 2013
P2, N=211, Completed, Sponsor: Genentech
Active, not recruiting --> Completed N=210210 --> 211
- New P4 trial: Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis (RA) in clinical remission in treatment with biological therapies Evaluaci (EUDRACT) - May 15, 2013
P4, N=28, Ongoing, Sponsor: FRANCISCO J. BLANCO GARC
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, HEOR: A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia (clinicaltrials.gov) - May 9, 2013
P=N/A, N=70, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=210210 --> 211 Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
P4 data: A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) (clinicaltrials.gov) - May 5, 2013
P=N/A, N=8250, Recruiting, Sponsor: AbbVie
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical: PsoBest - The German Psoriasis Registry (clinicaltrials.gov) - May 5, 2013
P=N/A, N=3500, Recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice (clinicaltrials.gov) - Apr 7, 2013
P=N/A, N=4208, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Completed
- || Humira (adalimumab) / AbbVie
Trial completion: Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use (clinicaltrials.gov) - Apr 1, 2013
P3, N=32, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Active, not recruiting --> Completed
- HEOR: Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis (clinicaltrials.gov) - Mar 14, 2013
P=N/A, N=1000, Not yet recruiting, Sponsor: Jochen Schmitt.
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial: ABILITY-3: Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis (clinicaltrials.gov) - Mar 7, 2013
P4, N=740, Recruiting, Sponsor: AbbVie
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Special Investigation in Patients With Crohn's Disease (All Patients Investigation) (clinicaltrials.gov) - Feb 28, 2013
P=N/A, N=1716, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS) (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=4500, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Humira (adalimumab) / AbbVie
Trial completion: A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA) (clinicaltrials.gov) - Feb 26, 2013
P4, N=308, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, HEOR: Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice (clinicaltrials.gov) - Feb 25, 2013
P=N/A, N=460, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: REACH: Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA (clinicaltrials.gov) - Feb 24, 2013
P=N/A, N=1000, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
New P4 trial: STARA: Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 13, 2013
P4, N=400, Recruiting, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct ) (clinicaltrials.gov) - Feb 11, 2013
P=N/A, N=5914, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct ) (clinicaltrials.gov) - Feb 5, 2013
P=N/A, N=5914, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting N=4500 --> 5914
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population (clinicaltrials.gov) - Jan 31, 2013
P=N/A, N=60, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, HEOR: Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life (clinicaltrials.gov) - Jan 30, 2013
P=N/A, N=200, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=4500 --> 5914 Recruiting --> Active, not recruiting
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Trial withdrawal: Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Jan 24, 2013
P2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Terminated --> Withdrawn
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab (clinicaltrials.gov) - Jan 21, 2013
P=N/A, N=155, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Terminated --> Withdrawn Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice (clinicaltrials.gov) - Jan 13, 2013
P=N/A, N=5747, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Efficacy Study of Adalimumab to Treat Interstitial Cystitis (clinicaltrials.gov) - Jan 9, 2013
P3, N=50, Active, not recruiting, Sponsor: ICStudy, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P3 trial: RA-COMPARE: An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate (clinicaltrials.gov) - Jan 8, 2013
P3, N=700, Recruiting, Sponsor: Sanofi
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Observational data: Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Jan 7, 2013
P=N/A, N=1360, Recruiting, Sponsor: UCB Pharma SA
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Enrollment open: SPIRIT-P1: A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - Jan 3, 2013
P3, N=412, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069 (clinicaltrials.gov) - Jan 1, 2013
P=N/A, N=125, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting N=172 --> 125
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice (clinicaltrials.gov) - Dec 23, 2012
P=N/A, N=550, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P2 trial: Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab (clinicaltrials.gov) - Dec 17, 2012
P2, N=88, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Combination therapy: CONCERTO: Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Dec 17, 2012
P3, N=395, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=172 --> 125 Active, not recruiting --> Completed
- || Humira (adalimumab) / AbbVie
Enrollment closed: Chronic Plaque Psoriasis (Ps) Registry (clinicaltrials.gov) - Dec 10, 2012
P=N/A, N=6000, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab. (clinicaltrials.gov) - Dec 6, 2012
P2, N=64, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab (clinicaltrials.gov) - Dec 6, 2012
P2, N=61, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Recruiting --> Completed
- New P4 trial: A randomised controlled trial to compare withdrawal of therapy versus continuing therapy in low disease states in psoriatic arthritis (EUDRACT) - Dec 3, 2012
P4, N=30, Ongoing, Sponsor: University of Leeds
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial) (clinicaltrials.gov) - Nov 29, 2012
P2/3, N=40, Active, not recruiting, Sponsor: University of Heidelberg
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice (clinicaltrials.gov) - Nov 27, 2012
P=N/A, N=300, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- || Olumiant (baricitinib) / Incyte, Eli Lilly
New P3 trial, P3 data: A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis. (EUDRACT) - Nov 26, 2012
P3, N=1280, Ongoing, Sponsor: Eli Lilly and Company`Lilly S.A.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient (clinicaltrials.gov) - Nov 7, 2012
P3, N=80, Recruiting, Sponsor: Hamad Medical Corporation
- | Humira (adalimumab) / Eisai, AbbVie
New P4 trial: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis (clinicaltrials.gov) - Nov 4, 2012
P4, N=106, Recruiting, Sponsor: Innovaderm Research Inc.
- |||||| Olumiant (baricitinib) / Incyte, Eli Lilly
Enrollment open: RA-BEAM: A Study in Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Nov 1, 2012
P3, N=1280, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Humira (adalimumab) / AbbVie
Enrollment open: Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis (clinicaltrials.gov) - Oct 27, 2012
P3, N=200, Recruiting, Sponsor: Clalit Health Services
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial, Combination therapy: Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC) (clinicaltrials.gov) - Oct 25, 2012
P4, N=100, Enrolling by invitation, Sponsor: University of Western Ontario, Canada
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate (clinicaltrials.gov) - Oct 25, 2012
P3, N=111, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||| Humira (adalimumab) / AbbVie
Enrollment open, HEOR: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (clinicaltrials.gov) - Oct 25, 2012
P3, N=455, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: HOPE 3: Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467)) (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=220, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting N=300 --> 220
- |||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Combination therapy: Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC) (clinicaltrials.gov) - Oct 24, 2012
P4, N=100, Enrolling by invitation, Sponsor: University of Western Ontario, Canada
N=300 --> 220 Not yet recruiting --> Enrolling by invitation